J&J's Stelara Gets EU Nod For Plaque Psoriasis In Children
Zacks Investment Research | Jan 23, 2020 09:12PM ET
Johnson & Johnson (NYSE:JNJ) announced that the European Commission (EC) has approved the label expansion of Stelara (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients aged between six and 11 years for whom there are limited biologic treatment options.
Notably, in December 2019, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending the marketing approval of Stelara to treat the above-mentioned patient population.
With the latest nod in the EU, Stelara becomes the first available biologic treatment to deal with the given patient population to selectively address the IL-23/IL-12 pathway, an important therapeutic target for the given condition.
The EC’s approval for plaque psoriasis in pediatric patients was based on data from the phase III CADMUS Jr study. Results from the same showed that treatment with Stelara led to improved signs and symptoms of plaque psoriasis as well as better health-related quality of life in children aged from six to 11 years, who are living with this chronic disease.Stelara is also under the FDA review for plaque psoriasis in pediatric patients.
Shares of J&J have increased 15.8% in the past year compared with the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.